~5,800
Median wRVUs / yr
Office E&M, infusion, bone marrow biopsy, and chronic care management — the codes that make up a heme/onc practice, with 2026 CMS wRVU values.
Compensation and productivity benchmarks pulled from public physician surveys and the 2026 Medicare Physician Fee Schedule.
The codes that drive the bulk of hematology & oncology billing, with current Work RVU values from the 2026 Medicare Physician Fee Schedule. Use these as a baseline — locality (GPCI) and modifiers adjust the final payment.
| Code | Description | wRVU | Type |
|---|---|---|---|
| 99213 | Office visit, est. patient, low (20 min) | 1.30 | E&M |
| 99214 | Office visit, est. patient, moderate (30 min) | 1.92 | E&M |
| 99215 | Office visit, est. patient, high (40 min) | 2.80 | E&M |
| 99204 | Office visit, new patient, moderate (45 min) | 2.60 | E&M |
| 99205 | Office visit, new patient, high (60 min) | 3.50 | E&M |
| 96413 | Chemotherapy administration, IV infusion, first hour | 0.28 | Procedure |
| 96415 | Chemotherapy administration, IV infusion, each additional hour | 0.19 | Procedure |
| 96365 | IV infusion, therapeutic, first hour | 0.21 | Procedure |
| 96367 | IV infusion, additional sequential drug, each | 0.19 | Procedure |
| 38221 | Bone marrow biopsy, needle or trocar | 1.28 | Procedure |
| 38222 | Bone marrow biopsy with aspiration | 1.44 | Procedure |
Source: 2026 Medicare Physician Fee Schedule (CMS). Values reflect the national, unadjusted Work RVU.
Where hematology & oncology productivity falls across the percentile distribution. Most RVU-based contracts target the median (50th percentile); high-volume practices push into the 75th-90th range.
MGMA-aligned 2024 estimates. Verify with your group's data source for contract negotiations.
Typical total compensation ranges across a hematology & oncology career. Numbers blend salary, RVU productivity, and bonus components reported in physician surveys.
First 1-3 years out of training. Base-heavy contracts; productivity bonuses begin to ramp.
Years 4-10. RVU-based comp dominates as case volume settles into a steady pattern.
10+ years, partnership track, ASC ownership, or high-volume practice settings.
Ranges synthesized from Doximity 2024 and AMGA / MGMA-aligned compensation reports. Actual offers vary by region, practice setting, and case mix.
Most RVU tools were built for one type of day. RVU Tracker handles the mix of clinic, procedures, and inpatient work that actually shows up on a hematology & oncology schedule.
Save your most-used codes as quick-add buttons. Log a visit in seconds between patients.
Add multiple codes per encounter; the tracker sums correctly with MPPR awareness when relevant.
Tag clinic vs. procedure days and see productivity per session. Decide where to add capacity.
Every code ships with current Work RVU values. Year-over-year updates roll out automatically.
Set your wRVU threshold. The tracker shows monthly pace and projects year-end totals.
Plug in your conversion factor and see real-time earnings. Compare offers during contract review.
A few high-leverage details that quietly cost RVUs (and revenue) when missed.
Chemo (96413/96415) is the primary, hydration (96360/96361) is secondary, push (96409) is tertiary. Sequential vs. concurrent matters. Document precisely — misordered billing is the most common revenue leak in heme/onc.
Office E&M (99213-99215) is separately billable on a chemo day with -25 if the visit addressed a separately significant problem (treatment plan, toxicity assessment). Documentation must clearly separate the work.
38222 (biopsy + aspiration) replaces what used to be billed as 38221 + 38220. Don't double-bill the components if you used the combined code; payers will deny the unbundled pair.
99490 / 99491 (CCM) is appropriate for cancer survivors with chronic surveillance needs. Many heme/onc practices underbill care management for survivorship work that legitimately qualifies.
2026 CMS data pre-loaded for every code. Designed for the cadence of a real hematology & oncology day.